Table 2.
Author | Age | Sex | Primary tumor | Histological type | Tx of HCM | Sx | CTx | RTx | Course of the tumor | Outcome of HCM | Effective Tx of HCM |
---|---|---|---|---|---|---|---|---|---|---|---|
Hoekman et al. [2] | 70 | F | Ovarian carcinoma | Adenocarcinoma | Pamidronate | Yes | No | No | Resection | Improvement | Operation |
Hydrocortisone | |||||||||||
Van den Eynden et al. [3] | 59 | M | Pancreatic neuroendocrine tumor | Neuroendocrine tumor | Pamidronate | Yes | Yes | No | Reduction | Improvement | Chemotherapy |
Zoledronic acid | |||||||||||
Shivnani et al. [4] | 57 | M | Renal cell carcinoma | Clear cell | Pamidronate | No | Yes | No | Progression | Improvement | Prednisolone |
Prednisolone | |||||||||||
Rodriguez-Gutierrez et al. [5] | 35 | M | Seminoma | Seminoma | Calcitonin | No | Yes | No | Reduction | Improvement | Chemotherapy |
Nemr et al. [6] | 60 | M | Lung cancer | Squamous | Calcitonin | No | No | No | Progression | No improvement | None |
Zoledronic acid | |||||||||||
Furosemide | |||||||||||
Ogawaa | 71 | M | Lung cancer | Squamous | Prednisolone | No | Yes | No | Progression | Improvement | Prednisolone |
Calcitonin |
CTx: chemotherapy; HCM: hypercalcemia of malignancy; RTx: radiation therapy; Sx: surgery; Tx: treatment. aPresent case.